8-K Announcements
6Material company update
Jan 7, 2026·SEC
Material company update
Nov 14, 2025·SEC
Material company update
Nov 6, 2025·SEC
Cidara Therapeutics, Inc.(CDTX)Earnings, Financials & Key Ratios
CDTX•NASDAQ
$221.38
Price updated Jun 20, 2026
AboutCidara Therapeutics, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of long-acting anti-infectives for the treatment and prevention of infectious diseases and oncology in the United States. The company's lead product candidate is rezafungin acetate, a novel molecule in the echinocandin class of antifungals for the treatment and prevention of invasive fungal infections, including candidemia and invasive candidiasis, which are fungal infections associated with high mortality rates. It also advances its Cloudbreak platform to develop conjugates for the prevention and treatment of influenza and other viral infections, such as RSV, HIV, and the SARS-CoV-2 strains causing COVID-19. The company was formerly known as K2 Therapeutics, Inc. and changed its name to Cidara Therapeutics, Inc. in July 2014. Cidara Therapeutics, Inc. was incorporated in 2012 and is based in San Diego, California.Show more
- Revenue$1M-94.5%
- EBITDA-$176M-552.6%
- Net Income-$170M-640.6%
- EPS (Diluted)-26.75-409.5%
- Gross Margin100%+272.7%
- EBITDA Margin-13793.65%-11817.7%
- Operating Margin-13811.92%-11784.1%
- Net Margin-13319.76%-13424.2%
- ROE-218.99%
CDTX Price & Volume
Cidara Therapeutics, Inc. (CDTX) stock price & volume — 10-year historical chart
Loading chart...
Clinical R&D Pivot Drives Massive Cash Burn
Investment Thesis • Updated 2025Q3
VerdictNegative
Growth:Contracting
Profitability:Negative
Financial:Adequate
Cash Flow:Burning
Primary Risk:Clinical trial milestone dependency
Key Thesis Takeaways
- Cidara Therapeutics has transitioned into a pure-play, milestone-dependent research platform, effectively eliminating commercial revenue streams while aggressively scaling R&D expenditures to $35.5 million in 2025Q3.
- While recent capital raises have bolstered the balance sheet to $293.7 million in cash, the company remains fundamentally reliant on clinical validation to offset its deep operating losses.
- Investors should monitor the sustainability of this burn rate, as the lack of recurring revenue and an accumulated deficit of $743.7 million present significant long-term solvency risks.
Verdict Logic
the company's reliance on cash reserves to fund a $88.6 million operating loss in 2025Q3, combined with the absence of recurring revenue, suggests a high-risk profile for long-term capital preservation.
CDTX Growth Metrics
Cidara Therapeutics, Inc. (CDTX) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-42.85%
3 Years-70.48%
TTM-100%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-50.03%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM53.79%
Return on Capital
10 Years-202.8%
5 Years-335.09%
3 Years-434.89%
Last Year-213.65%
CDTX Recent Earnings
Cidara Therapeutics, Inc. (CDTX) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 5/12 qtrs (42%)●Beat Revenue 4/12 qtrs (57%)
Q4 2025Latest
Nov 6, 2025Metric
Actual
Est
EPS
$1.43-6.7%
$1.34
Rev
—
—
Q3 2025
Aug 7, 2025Metric
Actual
Est
EPS
$1.65+11.8%
$1.87
Rev
—
—
Q2 2025
May 8, 2025Metric
Actual
Est
EPS
$1.66+69.5%
$5.45
Rev
—
—
Q2 2025
Mar 6, 2025Metric
Actual
Est
EPS
$5.38-1.9%
$5.28
Rev
—
$240,000
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q4 2025Latest | Nov 6, 2025 | $1.43vs $1.34-6.7% | — |
| Q3 2025 | Aug 7, 2025 | $1.65vs $1.87+11.8% | — |
| Q2 2025 | May 8, 2025 | $1.66vs $5.45+69.5% | — |
| Q2 2025 | Mar 6, 2025 | $5.38vs $5.28-1.9% | —vs $240,000 |
Based on last 12 quarters of dataView full earnings history →
Peers Comparison
Key metrics vs top competitors for Cidara Therapeutics, Inc. (CDTX)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $221.38 | $6.96B | -8.28 | -94.52% | -13319.76% | -218.99% | — | |
| $25.77 | $4.41B | 11.25 | 11.87% | 34.3% | 35.65% | — | |
| $37.39 | $2.22B | -5.25 | 48.03% | -639.84% | -34.11% | — | |
| $313.50 | $9.06B | -23.26 | -100% | — | -43.02% | — | |
| $14.51 | $336.87M | -3.78 | -3.42% | -89.56% | -64.04% | — | |
| $4.57 | $290.48M | -3.87 | 0.78% | -44.79% | -147.8% | — |
Compare CDTX vs Peers
Cidara Therapeutics, Inc. (CDTX) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
CDTX SEC Filings & Documents
Cidara Therapeutics, Inc. (CDTX) SEC filings — annual & quarterly reports (10-K, 10-Q)
Get notified when CDTX posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
CDTX Frequently Asked Questions
Cidara Therapeutics, Inc. (CDTX) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
What is Cidara Therapeutics, Inc.'s revenue?
Cidara Therapeutics, Inc. (CDTX) reported $1.3M in revenue for fiscal year 2024.
How fast is Cidara Therapeutics, Inc. growing?
Cidara Therapeutics, Inc. (CDTX) saw revenue decline by 94.5% over the past year.
Is CDTX profitable?
Cidara Therapeutics, Inc. (CDTX) reported a net loss of $184.7M for fiscal year 2024.
Dividend & Returns
What is CDTX's return on equity?
Cidara Therapeutics, Inc. (CDTX) has a return on equity (ROE) of -219.0%. Negative ROE indicates the company is unprofitable.
What is Cidara Therapeutics, Inc.'s free cash flow?
Cidara Therapeutics, Inc. (CDTX) had negative free cash flow of $132.9M in fiscal year 2024, likely due to heavy capital investments.